Peptide Therapeutics Market Size Expected to Reach USD 83.75 Bn by 2034
February 13, 2025 10:15 ET | Precedence Statistics
Ottawa, Feb. 13, 2025 (GLOBE NEWSWIRE) -- The global peptide therapeutics market size was valued at USD 49.13 billion in 2024 and is projected to surpass USD 83.75 billion by 2034. According to...
Zealand Logo (1).png
Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity
January 07, 2025 11:00 ET | Zealand Pharma
Press Release – No. 2 / 2025 Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity Copenhagen, Denmark, January 7, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL)...
Skyquest Logo
Peptide Therapeutics Market to Witness 5.94% CAGR by 2031 | SkyQuest Technology
September 27, 2024 08:00 ET | SkyQuest Technology Consulting Pvt. Ltd.
Westford, USA, Sept. 27, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that Peptide Therapeutics Market will attain the value of USD 68.4 Billion by 2031, with a CAGR of 5.94% during the forecast...
Zealand Logo (1).png
Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results
August 12, 2024 11:00 ET | Zealand Pharma
Press Release – No. 8 / 2024 Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results Copenhagen, Denmark, August 12,...
Logo.png
Global Peptide Therapeutics Market to Grow Significantly at a CAGR of ~10% by 2030| DelveInsight
July 17, 2024 13:00 ET | DelveInsight Business Research LLP
New York, USA, July 17, 2024 (GLOBE NEWSWIRE) -- Global Peptide Therapeutics Market to Grow Significantly at a CAGR of ~10% by 2030| DelveInsight  The increasing prevalence of conditions like...
zealand_logo_RGB_01.png
Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide
May 23, 2024 14:45 ET | Zealand Pharma
Company announcement – No. 27 / 2024 Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide Mean...
zealand_logo_RGB_01.png
Zealand Pharma Announces Financial Results for the Full Year 2023
February 27, 2024 01:00 ET | Zealand Pharma
Company announcement - No. 9 / 2024 Zealand Pharma Announces Financial Results for the Full Year 2023 Significant progress delivered across our obesity and rare disease assets while building a...
Emergen logo.png
Peptide Therapeutics Market Size Worth USD 75.92 Billion in 2032 | Emergen Research
January 17, 2024 12:58 ET | Emergen Research
Vancouver, Jan. 17, 2024 (GLOBE NEWSWIRE) -- The global peptide therapeutics market size was USD 42.70 Billion in 2022 and is expected to register a revenue CAGR of 6.0% during the forecast period....
zealand_logo_RGB_01.png
Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th
January 02, 2024 02:00 ET | Zealand Pharma
Press Release – No. 1 / 2024 Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th Copenhagen, Denmark, January 2, 2024 – Zealand...
zealand_logo_RGB_01.png
Zealand Pharma presents data for amylin analog ZP8396 at ObesityWeek
October 17, 2023 02:00 ET | Zealand Pharma
Press release – No. 13 / 2023 Zealand Pharma presents data for amylin analog ZP8396 at ObesityWeek Copenhagen, Denmark, October 17, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no....